The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 22, 2013

Filed:

Mar. 17, 2009
Applicants:

Arnold Van Loevezijn, Weesp, NL;

Wouter I. Iwema Bakker, Weesp, NL;

Axel Stoit, Weesp, NL;

Agatha A. M. Rensink, Weesp, NL;

Jennifer Venhorst, Weesp, NL;

Martina A. W. Van Der Neut, Weesp, NL;

Martin DE Haan, Weesp, NL;

Cornelis G. Kruse, Weesp, NL;

Inventors:

Arnold Van Loevezijn, Weesp, NL;

Wouter I. Iwema Bakker, Weesp, NL;

Axel Stoit, Weesp, NL;

Agatha A. M. Rensink, Weesp, NL;

Jennifer Venhorst, Weesp, NL;

Martina A. W. Van Der Neut, Weesp, NL;

Martin De Haan, Weesp, NL;

Cornelis G. Kruse, Weesp, NL;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 231/06 (2006.01); C07D 231/54 (2006.01); C07D 403/12 (2006.01); C07D 471/10 (2006.01); C07D 491/10 (2006.01);
U.S. Cl.
CPC ...
Abstract

This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.


Find Patent Forward Citations

Loading…